InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.003 -0.004 (-57.14%)+
Announcement
Release
26 Feb 2026 12:41PM
Price at Release
$0.007
Full Release
download
Summary
The half-yearly report for Percheron Therapeutics Limited details the financial performance for the period ending 31 December 2025. The company reported a loss after income tax of AUD 3,105,697 for the half-year, reflecting a decrease from the previous full year's loss of AUD 14,921,913. The total equity at the end of the period was recorded at AUD 7,137,852, down from AUD 10,003,873 at the beginning of the half-year. The decrease in equity was primarily due to the losses incurred. Percheron issued share capital of AUD 112,048,298, and reserves increased to AUD 1,862,310. The report also notes a payment of USD 2.0 million to Hummingbird Bioscience for a license agreement, contributing to the recognition of intellectual property as intangible assets valued at AUD 3,080,781. The company had 139,456,276 unlisted options outstanding as of 31 December 2025, and share-based payment expenses were noted. Basic and diluted earnings per share were recorded at (0.29) cents.
Key Points
  • Loss after income tax for half-year: AUD 3,105,697.
  • Total equity decreased to AUD 7,137,852.
  • Issued share capital stood at AUD 112,048,298.
  • Reserves increased to AUD 1,862,310.
  • USD 2.0 million paid to Hummingbird Bioscience for a license.
  • Intellectual property recognized as intangible assets: AUD 3,080,781.
  • 139,456,276 unlisted options outstanding.
  • Share-based payment expenses incurred.
  • Basic and diluted earnings per share: (0.29) cents.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.